Wave Chasing Huntington’s Accelerated Approval Based On Caudate Atrophy Surrogate

The biotech plans a pivotal trial that would support accelerated approval of the Takeda-partnered antisense oligonucleotide, WVE-003, and will discuss it with regulators before the end of the year.

Wave believes a registrational trial with about 150 patients could last 12 to 18 months. • Source: Shutterstock

Wave Life Sciences Ltd. expects to pitch using caudate atrophy as a surrogate endpoint to support accelerated approval of its WVE-003 in Huntington's disease to regulators by the end of the year.

Key Takeaways

Wave announced positive efficacy data for WVE-003 in Huntington’s disease, with statistically significant reductions in mutant huntingtin protein and promising imaging biomarker data.

The Cambridge, MA-based biotech's case may be helped by positive Phase Ib/IIa efficacy data, although potential safety concerns about neurofilament...